

31 March 2020

Australian Securities Exchange  
Level 40, Central Park  
152-158 St Georges Tce  
Perth WA 6000

Via email: [tradinghaltspert@asx.com.au](mailto:tradinghaltspert@asx.com.au)

Dear Sir/Madam

**MGC Pharmaceuticals Ltd – Voluntary Suspension Extension Request**

Pursuant to ASX Listing Rule 17.2, MGC Pharmaceuticals Ltd (ASX: MXC) (the “Company”) requests a voluntary suspension over the Company’s securities from the commencement of trade on Tuesday 31 March 2020.

In accordance with ASX Listing Rule 17.2 the Company provides the following information regarding the request:

1. The voluntary suspension extension request is to allow the Company to complete additional disclosure to its announcement, at the request of ASX, on a material agreement regarding a strategic joint venture with a Swiss company in relation to COVID-19.
2. The Company expects the voluntary suspension to end no later than the commencement of trade on Thursday 2 April 2020, when it anticipates it will be in a position to make a detailed announcement to the market in respect of the abovementioned transaction.
3. The Company is not aware of any reason why the voluntary suspension should not be granted, nor of any other information necessary to inform the market about the voluntary suspension.

On behalf of the Board

*[signed electronically without signature]*

Brett Mitchell  
**Executive Chairman**  
**MGC Pharmaceuticals Ltd**